The report gives a complete investigation of the Adalimumab Biosimilar Pipeline industry and key market improvements. The exploration record comprises of past and figure showcase data, prerequisite, territories of use, value strategies, and friend’s portions of the main organizations by topographical district. The Adalimumab Biosimilar Pipeline report separates the market size, by volume and worth, depending upon the kind of utilization and area.
Request sample copy of this report at
DelveInsights, Adalimumab – Biosimilar Insight, 2021, report provides comprehensive insights about 34+ companies and 35+ marketed and pipeline drugs in Adalimumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It works by blocking a protein (tumor necrosis factor or TNF) found in the body’s immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis. Adalimumab belongs to a class of drugs known as TNF blockers. By reducing joint swelling, this medication helps to reduce further joint damage and preserve joint function. After treatment with adalimumab, a decrease in levels of acute phase reactant proteins of inflammation (C reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-6) was measured compared to baseline in patients diagnosed with rheumatoid arthritis.
Adalimumab Biosimilars: Drugs Chapters
This segment of the Adalimumab report encloses its detailed analysis of various drugs in different stages of clinical development, including marketed, phase III, II, I and preclinical. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Adalimumab Biosimilars: Marketed Drugs
Abrilada is an FDA-approved biosimilar version of adalimumab. Abrilada (adalimumab-afzb) injection is supplied as a sterile, preservative-free solution for subcutaneous administration. The drug product is supplied as either a single-dose prefilled pen (Abrilada pen), as a single-dose 1 mL prefilled glass syringe, or as a single-dose institutional use vial. Enclosed within the pen is a single-dose 1 mL prefilled glass syringe. Though approved, it is not yet marketed in the US like several other manufacturers of approved biosimilar versions of adalimumab, Pfizer has signed a licensing agreement with AbbVie; under the agreement, Samsung would be able to launch the drug in November 2023.
Halimatoz is mostly used in adults when their conditions are severe, moderately severe or getting worse, or when patients cannot use other treatments. Halimatoz contains the active substance adalimumab and is a biosimilar medicine. The active substance in Halimatoz, adalimumab, is a monoclonal antibody (a type of protein) that has been designed to recognise and attach to a substance in the body called tumour necrosis factor (TNF). TNF is involved in causing inflammation and is found at high levels in patients with the diseases that Halimatoz is used to treat. By attaching to TNF, adalimumab blocks its activity, thereby reducing inflammation and other symptoms of the diseases.
Further product details are provided in the report..
Adalimumab Biosimilars: Emerging Drugs
MYL-1401A is an anti-TNF monoclonal antibody. This tumour necrosis factor inhibitor is a proposed biosimilar of HUMIRA (adalimumab). MYL-1401A is a recombinant human IgG1 monoclonal antibody and is being evaluated as an injectable therapy for the treatment of rheumatoid arthritis and plaque psoriasis.
CT-P17 is the first high-concentration type of medicine for a biosimilar made of adalimumab. The company has differentiated CT-P17 from existing Humira biosimilars by halving the dosage. By taking the latest trend into account, Celltrion has also removed citrate, which can cause pain in self-injection, from its latest product. If Celltrion launches CT-P17, it will be able to complete a robust portfolio of CT-P17 in the global autoimmune disorder treatment market. CT-P17 acts as immunosuppressants and tumour necrosis factor alpha inhibitors.
Further product details are provided in the report..
Adalimumab: Therapeutic Assessment
This segment of the report provides insights about the different Adalimumab biosimilars segregated based on following parameters that define the scope of the report, such as:
Major Players in Adalimumab
There are approx. 34+ key companies which are developing the therapies for Adalimumab.
DelveInsights report covers around 35+ products under different phases of clinical development like
Marketed stage products
Late stage products (BLA Filed and Phase III)
Mid-stage products (Phase II and
Early-stage products (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Adalimumab pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Adalimumab: Pipeline Development Activities
The report provides insights into different therapeutic candidates in marketed, phase III, II, I and preclinical stage. It also analyses Adalimumab biosimilars drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Adalimumab biosimilar drugs.
The companies and academics are working to assess challenges and seek opportunities that could influence Adalimumab R&D. The therapies under development are focused on novel approaches to treat/improve Adalimumab.
In December 2020, Shanghai Henlius Biotech adalimumab biosimilar candidate HLX03 has been approved by Chinas National Medical Products Administration for the treatment of rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis.
Innovent Biologics announced that in September 2020, SULINNO (adalimumab biosimilar) has been approved by the National Medical Products Administration (NMPA) for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriasis, polyarticular juvenile idiopathic arthritis in China.
In July 2020, the FDA has approved an adalimumab biosimilar (Hulio) from Fujifilm Kyowa Kirin Biologics, making it the sixth adalimumab biosimilar to AbbVies reference product Humira that has been approved and the 28th biosimilar approved by the FDA. Mylan will handle the commercialization in the United States.
In March 2020, Alvotech announced that it entered into an exclusive license partnership with DKSH, a market expansion services provider, for the commercialization of AVT02, a biosimilar to AbbVies HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets.
Adalimumab Biosimilars Report Insights
Adalimumab Biosimilar Pipeline Analysis
Impact of Drugs
Adalimumab Biosimilar Report Assessment
Marketed Product profiles
Pipeline Product Profiles
Inactive drugs assessment
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Adalimumab Biosimilars
How many Adalimumab biosimilars are developed by each company
How many emerging biosimilars are in mid-stage, and late-stage
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Adalimumab biosimilars therapeutics
What are the clinical studies going on for Adalimumab biosimilars and their status
What are the key designations that have been granted to the emerging drugs
Shanghai Henlius Biotech
Mylan and Fujifilm Kyowa Kirin Biologics
Meiji Seika Pharma
Harvest Moon Pharmaceuticals
Gene Techno Science
Fresenius Kabi, Germany [Bought from Merck KGaA (Merck Group)
Bionovis/The Instituto Vital Brazil
Inquire for discount at
The report collects relevant data in a method that allows readers to understand individual elements and their interactions in the current market scenario. It focuses on the necessary modifications for new and existing businesses to evolve and adapt to future trends in this market. In addition, it helps the reader to identify salient features of the Global Adalimumab Biosimilar Pipeline Market Research Report 2021 and provides sufficient statistical data to understand its operation. It also examines possible deficiencies along with the problems encountered by new and predominant companies.
To conclude, this Adalimumab Biosimilar Pipeline Market report covers all the necessary financial, economic and social factors relevant to the industry enhancing the reader with the information required to make an informed decision.
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Key Features of the Report:
- The report provides granular level information about the market size, regional market share, historic market (2015-2019) and forecast (2020-2027)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup’s details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market.
Complete report is available at
There are 10 Chapters to deeply display the Adalimumab Biosimilar Pipeline Market.
Chapter 1 to analyze the top manufacturers of Adalimumab Biosimilar Pipeline, with sales, revenue and price of Adalimumab Biosimilar Pipeline in 2020-2027.
Chapter 2, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2020-2027.
Chapter 3, to show the global market by regions, with sales, revenue and market share of Adalimumab Biosimilar Pipeline, for each region, from 2020-2027.
Chapter 4, 5, 6 and 7 to analyze the key regions, with sales, revenue and market share by key countries in these regions.
Chapter 8 and 9, to show the market by type and application, with sales market share and growth rate by type, application, from 2020-2027.
Chapter 10 Adalimumab Biosimilar Pipeline Market forecast, by regions, type and application, with sales and revenue, from 2020-2027.
Research Foretell is an information service company that provides market research, custom, and consulting services. Decision-making is complicated and we help you to solve your biggest puzzle, by identifying, analyzing, and monitoring the recent developing technologies and markets. Research Foretell is always forefront on classifying new opportunity in the market; with us you always have the first mover advantage.
Robert Claussen (Head of Sales) – Research Foretell